oasis 1 trial oral semaglutide 50 mg weight loss results taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 🥼🧪Slide Deck: Efficacy and safety

We can see supply really start to step up over the coming years with new manufacturing facilities and the leveraging of different devices (e.g., Kwikpen etc.) to expand capacity

Where outsourcing facilities have made a difference There is credible evidence that outsourcing facilities have played a supportive role in mitigating the clinical impact of some shortages, particularly in acute care settings

Thats a big deal, especially as we get older and cant afford to lose what little muscle volume we already struggle to hang onto

So there may be issues around that as well

Everyone's different: What works for one person might not work for another

It created an affirmative recommendation, but one more distinction remains: an advisory recommendation is still not the operative FDA list